Stocks were looking for direction on Tuesday after Monday’s drop in the Dow Jones Industrial Average was the first down-day in nine trading sessions. Oh, and the meme-stock craze is back at the same time housing earnings look soft. The market is awaiting key inflation and retail sales data this week to get a better handle on whether the Federal Reserve can begin to start reversing any of its 11 interest rate hikes.
Oggonomics is always on the hunt for ideas and research that can benefit long-term investors and short-term traders alike. The daily analyst upgrades, downgrades and initiations are often a strong source for new ideas. Many analyst calls are “strategic bull” calls by their nature as the “stocks to buy” may even occur when the stock market or a company’s sector are weak.
Other analyst calls covering their picks of stocks to buy may have very long-term outlooks. The latter “bullish” calls may seem more permanent to investors than they do strategic. And some other analyst calls are quite negative as they feature various stocks to sell. Some of those analyst calls on “stocks to sell” can also be strategic or feature long-term negative views.
Investors should always consider that no analyst call should act as a sole reason to buy or sell a stock. These daily analyst calls and the impact from the calls should also help prove one of the Oggonomics mantras that the Efficient Market Hypothesis is not accurate in its assumptions.
BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN) was started as Outperform with a $113 price target (versus $80.50 close) at Evercore ISI.
Blueprint Medicines Corporation (NASDAQ: BPMC) was started as Overweight with a $140 price target (versus $108.05 prior close) at Stephens & Co.
CEMEX, S.A.B. de C.V. (NYSE: CX) was started with an Underperform rating and was assigned a $9.00 price target at RBC Capital. CEMEX previously closed at $7.95 with a $10.31 consensus analyst price target.
Elevation Oncology, Inc. (NASDAQ: ELEV) was started as Overweight with a $8.00 price target (versus $3.54 prior close) at Stephens & Co.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) was started as Overweight with a $20 price target (versus $11.36 prior close) at Stephens & Co.
Moderna, Inc. (NASDAQ: MRNA) was started as In-Line with a $120 price target (versus $125.67 prior close) at Evercore ISI.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was started as Outperform with a $175 price target (versus $136.15 prior close) at Evercore ISI.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was started as Outperform with a $1150 price target (versus $976.96 prior close) at Evercore ISI.
Roblox Corporation (NYSE: RBLX) was down heavily last week after earnings. Roblox was downgraded to Neutral from Buy and its price target was cut to $35 from $55 at Roth MKM. Roblox closed at $30.96 ahead of the call and shares were indicated down 0.2% on Tuesday morning.
Tencent Music Entertainment Group (NYSDE: TME) was reiterated as Buy and its price target was raised to $17 from $15 at Mizuho. The stock closed up 10.9% at $14.80 the prior day with a consensus analyst target price of $12.22.
Ulta Beauty, Inc. (NASDAQ: ULTA) was maintained with a Hold rating and its price target was cut to $475 from $565 at Stifel. Ulta Beauty shares closed at $403.96 after earnings and ahead of this call with a $551.29 consensus analyst price target.
In case you missed Monday’s top analyst upgrades and downgrades, they were in shares of Cisco, Delta, NVIDIA, PENN, SolarEdge, Southwest, T.I., Visa and many more.
